media – Page 166 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Keytruda sold $29.5 billion last year, and Merck suspended shipments of HPV vaccines to the Chinese market

On February 4, Merck announced its fourth quarter financial report for 2024 and its full-year performance last year. Of the $64.2 billion in sales for the year, its PD-1 monoclonal antibody product pembrolizumab (trade name Keytruda, commonly known as “Keytruda”) accounted for nearly half, with sales of $29.5 billion. Merck also announced that it would suspend shipments of HPV vaccine products Gardasil/Gardasil 9 to the Chinese market from February this year, and this decision will last at least until the middle of this year. Merck China said that this decision was mainly affected by the overall market environment, weak consumer demand and high channel inventory; it also maintains full confidence in the potential of the Chinese market. Suspending shipments to the Chinese market from this month At the same time as announcing its financial report, Merck announced a highly anticipated decision, namely, from February this year, it will suspend shipments ...
- Source: drugdu
- 318
- February 7, 2025
The application for marketing authorization of the independently developed drug of the holding subsidiary was approved by the EU

On February 5, Fosun Pharma announced that the marketing authorization application (MAA) of slulizumab injection (i.e., anti-PD-1 monoclonal antibody) independently developed by the holding subsidiary Shanghai Fuhong Henlius Biotech Co., Ltd. and its holding subsidiaries (collectively referred to as “Fuhong Henlius”) for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) was recently approved by the European Commission (i.e., the European Commission). Accordingly, the drug has obtained centralized marketing authorization in all EU member states and Iceland, Liechtenstein and Norway (European Economic Area countries respectively), and has become the first anti-PD-1 monoclonal antibody approved by the EU for the treatment of extensive-stage small cell lung cancer (ES-SCLC). https://finance.eastmoney.com/a/202502063311927270.html
- Source: drugdu
- 298
- February 7, 2025
【EXPERT Q&A】What are the differences between generic drugs and original drugs?

Drugdu.com expert’s response: Detailed Comparison Between Generic Drugs and Originator Drugs I. Definition and Background Originator Drugs: These are innovative drugs that are originally researched and developed by companies that hold the patent rights for the medication. These new drugs typically undergo long-term safety evaluations and complete Phase I to III (and sometimes Phase IV) clinical trials, followed by continuous post-marketing monitoring of their efficacy. The research and development (R&D) of originator drugs are usually initiated by large, financially strong pharmaceutical companies, taking up to fifteen years from R&D to market launch, with costs reaching billions of dollars. Generic Drugs: These are drugs that are developed after the patent protection period (typically 20 years) of an originator drug expires, based on research into the main active ingredient of the originator drug. The R&D process for generic drugs is relatively straightforward, involving the replication of the main molecular structure of the ...
- Source: drugdu
- 824
- February 7, 2025
Nepal launches national HPV vaccination program, expected to benefit more than 1.68 million girls

The Nepali government officially launched the HPV vaccination program nationwide on the 4th, and it is expected to vaccinate more than 1.68 million girls aged 10 to 14 to prevent cervical cancer and other related diseases. Nepali Prime Minister Oli attended the launch ceremony in the capital Kathmandu on the same day and presented vaccination materials to health workers. The vaccination program is led by the Ministry of Health and Population of Nepal and supported by the Global Vaccine Alliance (GAVI). It will be carried out nationwide from February 4 to 18, 2025. It is reported that a total of 18,900 schools in Nepal have been designated as vaccination centers, and another 8,200 medical institutions will provide vaccination services to the public. The Ministry of Health and Population of Nepal said that cervical cancer is the second most common cancer among women in Nepal and the leading cause of cancer ...
- Source: drugdu
- 350
- February 6, 2025
Uganda launches vaccine trial for Sudan Ebola virus

Kampala, February 4: Uganda’s Ministry of Health, the World Health Organization and other partners launched the world’s first vaccine trial for Sudan Ebola virus on February 3 local time. On January 30 local time, the Ugandan Ministry of Health announced that the country had an Ebola outbreak again after a lapse of two years, and a nurse in the capital Kampala died of Ebola virus infection. A statement issued by the WHO said that after the outbreak, Uganda’s local leading researchers prepared for the trial within 4 days with the support of the WHO and other partners. This is the first clinical efficacy trial of a vaccine against Sudan Ebola virus. Reuters reported that the trial will mainly target contacts of confirmed cases. According to the Associated Press, on February 3, two more relatives of the deceased nurse were confirmed to be infected with Ebola virus. The Ugandan government is ...
- Source: drugdu
- 233
- February 6, 2025
Merck will suspend the supply of HPV vaccine Gardasil to the Chinese market

On February 4, local time, Merck announced the suspension of the supply of HPV vaccine Gardasil to China, and the suspension is expected to last at least until the middle of the year. The financial report released by Merck on the same day showed that the company’s fourth quarter sales were US$15.6 billion, a year-on-year increase of 7%, of which Gardasil sales fell 17% year-on-year to US$1.55 billion. Merck said the main reason was the reduction in demand in China. In January this year, Merck’s HPV vaccine Gardasil was approved for marketing by the National Medical Products Administration for multiple new indications, suitable for males aged 9 to 26, becoming the first and currently the only approved HPV vaccine for men in China. https://finance.eastmoney.com/
- Source: drugdu
- 248
- February 6, 2025
mRNA RSV vaccine applied for clinical trials in the United States

Aimi Vaccine’s mRNA vaccine series product research and development has made new progress. The company announced on February 5 that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently applied for clinical trials to the U.S. Food and Drug Administration (FDA). According to the announcement, in preclinical animal trials, the test results of third-party testing units showed that Aimi’s mRNA RSV vaccine specific IgG antibody titer, true virus neutralizing antibody titer, and specific T cell immunity were significantly higher than the internationally listed mRNA RSV control vaccine. As one of the main pathogens causing lower respiratory tract infections in infants and young children, the market demand for its vaccine is also huge. The global sales of RSV vaccines in 2023 were US$2.46 billion. According to the forecast of Zhushi Consulting, the global market size of RSV vaccines is expected to reach approximately US$16.7 billion by 2030. If the ...
- Source: drugdu
- 262
- February 6, 2025
KIMES BUSAN

Organiser：Korea E&EX Exhibition Company Time：September 26 – 28, 2025 Address：55 Apec-ro, Haeundae-gu, Busan, 612-704, South Korea Exhibition hall：Busan Exhibition & Convention Center Product range: Medical Equipment: Medical technology equipment, consumables, medical electronic equipment, ophthalmic equipment and protective products, surgical instruments, emergency response equipment, hospital, dental, and medical equipment, dental service equipment and disposable medical products, disposable medical products for hospitals and households, hospital dentistry, medical data processing systems, dental plastic surgery, rehabilitation equipment, etc. In Vitro Diagnostics & Clinical Laboratory Equipment: Endoscopic systems, B-mode ultrasound, examination equipment, ENT treatment instruments, dynamic analysis instruments, comprehensive laboratory solutions, clinical diagnostic equipment, diagnostic reagents, precision medicine, POCT (Point-of-Care Testing) home diagnostic equipment, clinical laboratory equipment. Rehabilitation and Nursing Products: Orthopedic devices, walkers, hearing aids, auditory warning devices for the blind, manual wheelchairs, electric wheelchairs, crutches, walking aids, massage devices, health care clothing, fitness equipment, training machines, wrist and ankle braces, wearable neck ...
- Source: drugdu
- 552
- February 6, 2025
the equity transfer contract has come into effect

On February 4, Chongqing Pharmaceutical Holdings (000950) issued an announcement on the progress of the proposed change in the equity structure of the controlling shareholder. The company disclosed a relevant indicative announcement on January 11, 2025. Chongqing Chemical and Pharmaceutical Holdings (Group) Co., Ltd., a shareholder of the controlling shareholder Chongqing Pharmaceutical and Health Industry Co., Ltd., and Chongqing Yufu Holdings Group Co., Ltd. signed an equity transfer contract, intending to transfer 49% of Chongqing Chemical and Pharmaceutical Holdings to Chongqing Yufu. It is worth noting that the actual controllers of Chongqing Chemical and Pharmaceutical Group and Chongqing Yufu are both the Chongqing State-owned Assets Supervision and Administration Commission. According to the announcement, as of January 27, 2025, the company has received the “Notice Letter” from Chongqing Medical Health, confirming that Chongqing Chemical and Pharmaceutical Group has obtained the approval of the Chongqing State-owned Assets Supervision and Administration Commission, and ...
- Source: drugdu
- 464
- February 5, 2025
Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%

Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%. Galaxy Securities said that the pharmaceutical sector has undergone a long period of adjustment, the overall valuation is at a low level, and the public offering positions are underweight. In 2025, under the policy background of supporting and guiding the development of commercial insurance, the payment side is expected to improve marginally, and innovative drugs and equipment are expected to benefit. The pharmaceutical market will usher in a recovery, and structural opportunities still exist. From the perspective of short-term and medium- and long-term deterministic growth, targets are selected, and innovative drugs and industrial chains are optimistic about the continued good performance this year. Investors without stock accounts can seize investment opportunities in innovative drugs through the link fund (014118) of the innovative drug Shanghai-Shenzhen-Hong Kong ETF. Source: https://finance.eastmoney.com/
- Source: drugdu
- 338
- February 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.